Applied Genetic Technologies Corporation (AGTC)
Price:
0.39 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
NEWS
Make Money With Penny Stocks in November? 3 Methods to Use
pennystocks.com
2022-10-25 08:29:21Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AGTC to Participate in Upcoming Investor Conferences
globenewswire.com
2022-09-01 08:00:00GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
AGTC to Participate in Upcoming Investor Conferences
globenewswire.com
2022-08-01 16:05:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
globenewswire.com
2022-07-07 08:00:00July 7, 2022 at 8:00 AM EDT July 7, 2022 at 8:00 AM EDT
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
businesswire.com
2022-06-09 08:00:00SEATTLE, BOSTON & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothe
AGTC to Participate in Upcoming Investor Conferences
globenewswire.com
2022-03-08 16:05:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that management will be participating in the following virtual investor conferences:
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-02-14 13:01:03Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
globenewswire.com
2022-02-07 08:00:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter ended December 31, 2021 before the market opens on Monday, February 14, 2022. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
zacks.com
2021-11-09 09:56:31Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
globenewswire.com
2021-10-19 08:00:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.
AGTC Announces Two Key Leadership Team Appointments
globenewswire.com
2021-10-14 17:00:00- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
globenewswire.com
2021-10-12 11:08:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021.
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
globenewswire.com
2021-09-27 08:00:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
benzinga.com
2021-09-24 09:59:49After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems. The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a.
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-09-23 22:38:06Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
globenewswire.com
2021-09-23 16:05:00-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-
No data to display
Make Money With Penny Stocks in November? 3 Methods to Use
pennystocks.com
2022-10-25 08:29:21Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AGTC to Participate in Upcoming Investor Conferences
globenewswire.com
2022-09-01 08:00:00GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
AGTC to Participate in Upcoming Investor Conferences
globenewswire.com
2022-08-01 16:05:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
globenewswire.com
2022-07-07 08:00:00July 7, 2022 at 8:00 AM EDT July 7, 2022 at 8:00 AM EDT
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
businesswire.com
2022-06-09 08:00:00SEATTLE, BOSTON & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothe
AGTC to Participate in Upcoming Investor Conferences
globenewswire.com
2022-03-08 16:05:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that management will be participating in the following virtual investor conferences:
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-02-14 13:01:03Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
globenewswire.com
2022-02-07 08:00:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter ended December 31, 2021 before the market opens on Monday, February 14, 2022. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
zacks.com
2021-11-09 09:56:31Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
globenewswire.com
2021-10-19 08:00:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.
AGTC Announces Two Key Leadership Team Appointments
globenewswire.com
2021-10-14 17:00:00- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
globenewswire.com
2021-10-12 11:08:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021.
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
globenewswire.com
2021-09-27 08:00:00GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
benzinga.com
2021-09-24 09:59:49After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems. The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a.
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-09-23 22:38:06Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
globenewswire.com
2021-09-23 16:05:00-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-